438 | ORELABRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM A GLOBAL PHASE 1/2 STUDY
Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available
10.1002/hon.70094_438